DBC receives US FDA approval to market PulseFlowDF

RNS Number : 4709J
Port Erin Biopharma Investments Ltd
17 December 2015
 

17 December 2015

 

Port Erin Biopharma Investments Limited

("PEBI" or the "Company")

 

Diabetic Boot Company Limited receives US FDA approval to market PulseFlowDF in US

PEBI is pleased to announce that the Diabetic Boot Company Limited ("DBC"), in which it recently acquired 7,105 shares via a placement, has received a letter from the US Food and Drug Administration ("FDA") confirming that the product PulseFlowDF, being developed for the treatment of diabetic foot ulcers, can be marketed in the United States. This follows the submission by DBC of a Section 510(k) premarket notification and two rounds of questions from the FDA which DBC has responded to during 2015. DBC is now moving forward with plans to commence sales of PulseFlowDF in the United States.

Nick Hyde, the chairman of DBC noted that "receipt of approval to market a product from the FDA under section 510(k) is major milestone for any company and one that marks the start of an exciting next phase for us".

-ends-

 

For further information please contact:-

 

Denham Eke, Port Erin Biopharma Investments Limited Tel: +44 1624 639396

 

Roland Cornish / James Biddle, Beaumont Cornish Limited (Nomad) Tel: +44 (0) 207 628 3396

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEASAXFLLSFFF
UK 100

Latest directors dealings